Obsession Climbs to 19% for Best Original Screenplay With No Precursor Support

---

Obsession's Oscar Odds Just Doubled, But There's No Nomination to Back It Up

A horror film made for $750,000 has grossed $373 million worldwide, outpacing Ryan Coogler's Sinners to become the highest-grossing original live-action film of the decade. That commercial dominance is now bleeding into awards speculation the data cannot support.

Obsession's implied probability for Best Original Screenplay at the 2027 Oscars has surged from 9% to 19% across Kalshi and Polymarket over the past three days, a full doubling in a category where the film holds zero confirmed nominations, zero precursor wins, and zero guild recognition. The 2026 Oscar for Best Original Screenplay was already awarded to Sinners in March, meaning this market is pricing a 2027 race that won't resolve until March 14, 2027. No catalyst within the last 72 hours, such as a guild screening, a screenplay award shortlist, or a trade publication endorsement, clearly accounts for the move.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Obsession

Consensus YES price across 2 venues

8%average

KalshiBest YES price7¢Polymarket9¢

Tie

Consensus YES price across 1 venues

0%average

KalshiBest YES price2¢

Wild Horse Nine

Consensus YES price across 2 venues

50%average

PolymarketBest YES price48¢Kalshi54¢

The Debut

Consensus YES price across 2 venues

23%average

KalshiBest YES price20¢Polymarket26¢

Current new-user offer · Kalshi

Get a $35 trading bonusCode PRED35

New users only. Eligibility restrictions and terms apply.

View current offer

The spread between platforms tells its own story. Kalshi prices Obsession at 16%, while Polymarket sits at 22%, a 6-percentage-point gap that suggests retail-driven momentum rather than informed positioning. When sharp money moves a contract, platforms tend to converge quickly. They haven't.

---

Obsession's Box Office Dominance Is Rewriting the Conversation

The raw numbers explain why bettors are paying attention. Obsession premiered in the United States on May 15, 2026, after debuting at the 2025 Toronto International Film Festival. It has since grossed $373 million worldwide on a production budget of just $750,000, a return-on-investment ratio that dwarfs virtually every film in modern history. Sinners, by comparison, cost $90 million to produce and topped out at $370 million globally.

That level of cultural saturation creates a gravitational pull in prediction markets. Bettors conflate visibility with viability. When a film dominates social media discourse, generates mainstream media coverage, and outearns everything in its release window, casual participants begin pricing it into every category, whether or not the film fits the historical profile of winners in those categories.

The mechanism is straightforward: popularity liquidity. More people know about Obsession than about any plausible 2027 screenplay contender that hasn't even been released yet, so more people are willing to buy contracts on it. That doesn't make the bet smart. It makes the contract liquid.

---

Best Original Screenplay Is a Different Animal: What Obsession Actually Faces

Here is the strongest case against this market move, and it deserves full weight.

Best Original Screenplay is the most writer-centric category at the Oscars. It rewards structure, dialogue, and narrative ambition as evaluated by the Writers Branch, not audience turnout. The last decade of winners includes films like Parasite, Promising Young Woman, Belfast, and Anatomy of a Fall. These are intimate, dialogue-heavy, structurally inventive screenplays. Coogler's Sinners, which swept the BAFTA, Critics' Choice, and WGA Awards before winning the Oscar in March 2026, fits that mold: a genre film elevated by a screenplay the industry recognized as exceptional across every precursor body.

Obsession has none of that infrastructure. No WGA nomination. No Critics' Choice mention for its script. No screenplay-specific praise from the major trade publications that shape Academy voting. The film premiered at TIFF in September 2025 and has been in wide release since May 2026. If screenplay-specific buzz were building, it would have surfaced by now.

Horror films face an additional structural barrier. The Academy has historically undervalued horror in writing categories. Get Out (2017) is the notable exception, and Jordan Peele's screenplay won in part because it was recognized as social commentary first, horror second. Obsession's premise, a hopeless romantic who breaks a mysterious "One Wish Willow" and faces sinister consequences, reads as genre-forward. That framing rarely earns screenplay nominations, let alone wins.

The 2027 race will also include films that haven't screened yet. Fall festival premieres at Venice, Telluride, and Toronto in September 2026 will introduce entirely new contenders with fresh critical momentum. Obsession will be competing against screenplays bettors cannot yet name, which makes a 19% implied probability feel premature by at least six months.

---

The Bull Case for Obsession's Screenplay Nomination: Is the Market Seeing Something?

Dismissing the move entirely would be intellectually lazy. There are reasons, however thin, why Obsession could earn a legitimate screenplay nomination.

First, the film's micro-budget origin story is itself a narrative the Academy responds to. A $750,000 film outearning $90 million blockbusters is the kind of underdog story that generates goodwill among voting members who see themselves as champions of original creative vision. The screenplay is the foundation of that story: someone wrote something so compelling that audiences showed up 497 times over its budget.

Second, TIFF premieres have a strong track record of producing eventual Best Original Screenplay nominees. The festival's Platform Prize and People's Choice Award often identify films that end up in the conversation. If Obsession generated strong industry buzz at its September 2025 debut, that early positioning could carry forward.

Third, the Academy expanded its membership substantially after 2020, bringing in younger, more genre-friendly voters. Horror's ceiling in screenplay categories may be higher than historical data suggests. If Obsession's script contains the kind of structural twist that generates post-screening conversation (the "One Wish Willow" premise implies a narrative turn), it could attract attention from a voting body more open to genre work.

None of this constitutes evidence. It constitutes possibility. And 19% is not a prediction of a win. It is a one-in-five chance of winning a category in which the nominee list itself hasn't been determined. That framing matters: bettors are not saying Obsession will win. They are saying there's roughly a one-in-five chance it does. Given the film's cultural footprint and the uncertainty inherent in a race seven months from resolution, that number is aggressive but not absurd.

The honest read on this market: Obsession at 19% is a bet on cultural momentum sustaining itself through an awards season that hasn't started. The film has earned the right to be discussed. It has not earned the right to be priced as a top-tier contender in a screenplay race where every historical indicator argues against it. If no guild recognition or precursor nominations materialize by December 2026, this contract is overvalued. If they do, the current buyers will look prescient. Right now, the evidence favors the skeptics.